VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, December 31, 2025
Stock Comparison
CME Group Inc. vs Novo Nordisk A/S
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
CME Group Inc.
CME · NASDAQ
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into CME Group Inc.'s moat claims, evidence, and risks.
View CME analysisNovo Nordisk A/S
NOVOB · Nasdaq Copenhagen
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Novo Nordisk A/S's moat claims, evidence, and risks.
View NOVOB analysisComparison highlights
- Moat score gap: Novo Nordisk A/S leads (85 / 100 vs 81 / 100 for CME Group Inc.).
- Segment focus: CME Group Inc. has 3 segments (81.4% in Trading and Clearing (Derivatives + Cash Markets Platforms)); Novo Nordisk A/S has 3 segments (71.1% in Diabetes care).
- Moat breadth: CME Group Inc. has 10 moat types across 5 domains; Novo Nordisk A/S has 5 across 3.
Primary market context
CME Group Inc.
Trading and Clearing (Derivatives + Cash Markets Platforms)
Exchange-traded derivatives (futures and options) trading and central counterparty clearing; plus electronic cash markets matching (U.S. Treasuries/repo, spot FX) tied to CME platforms
Global (core U.S. footprint with international participation)
Institutional and professional traders; commercial hedgers; banks; broker-dealers; futures commission merchants (FCMs); asset managers; proprietary trading firms; governments and central banks
Market operator (exchange/venue) + central counterparty clearing provider
81.4%
Novo Nordisk A/S
Diabetes care
Diabetes pharmaceuticals (GLP-1 for type 2 diabetes, insulin, and related therapies)
Global
Payers/providers and patients (via wholesalers/pharmacies/hospitals)
Originator pharma (R&D, regulatory, manufacturing, commercialization)
71.1%
Side-by-side metrics
Moat coverage
Shared moat types
CME Group Inc. strengths
Novo Nordisk A/S strengths
Segment mix
CME Group Inc. segments
Full profile >Trading and Clearing (Derivatives + Cash Markets Platforms)
Oligopoly
Market Data and Information Services
Monopoly
Access, Connectivity and Other Exchange Services
Monopoly
Novo Nordisk A/S segments
Full profile >Diabetes care
Oligopoly
Obesity care
Duopoly
Rare disease
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.